Tagged Articles

Astra Zeneca 4 articles

FDA lifts boxed warning on combination asthma drugs

The boxed warning about asthma-related death has been removed from the labels of medicines that contain both an inhaled corticosteroid (ICS) and long-acting beta agonist (LABA). The safety label update was based after a Food and Drug Administration (FDA) review of four large clinical safety trials that showed treating asthma with LABAs along with ICS does not cause significantly more asthma-related side effects than treatment with ICS alone. More information about the four trials referenced by the FDA are now included in the Warnings and Precaution section of the drug labels. The information states that LABA when used with ICS ... Read More

AstraZeneca refuses Pfizer’s final offer to move forward with merger; now in cool-down period

What would have been the world’s largest drug company merger has been called off last-minute by Pfizer. AstraZeneca, the company that was to be bought, refused to take up Pfizer’s final offer of £55 a share – an offer that many believed would get AstraZeneca to the table for negotiations. “Following the AstraZeneca board’s rejection of the proposal, Pfizer announces that it does not intend to make an offer for AstraZeneca,” Pfizer said in a short news release. Pfizer, the largest drug company in the world currently, says that it chooses not to go hostile, but would rather let the ... Read More

Europe approves new combination diabetes treatment despite bladder cancer concerns

European drug regulators have approved AstraZeneca and Bristol-Myers Squibb’s combination type 2 diabetes drug Xigduo, making it the first treatment to combine a SGLT2 inhibitor with metformin. Xigduo is a combination of the widely used diabetes drug metformin and dapagliflozin, a new diabetes treatment sold in Europe as Forxiga. It was approved earlier this month by the U.S. Food and Drug Administration (FDA) under the name Farxiga. Dapagliflozin is in a new class of diabetes drugs known as SGLT2 inhibitors. Johnson & Johnson’s SGLT2 Invokana was approved in the U.S. in 2013. Other SGLT2 drugs are currently in development. The ... Read More

Trial on experimental obesity drug halted after participant suffers serious reaction

Astra Zeneca and Palatin Technologies have halted a phase 1 trial of an experimental obesity drug after a participant in the study suffered a severe adverse event. The drug, known as AZD2820, is a melanocortin-4 receptor partial agonist. Mutations in the melanocortin-4 receptor have been associated with inherited human obesity, and is the most commonly known genetic defect predisposing people to obesity. It is suspected that the participant may have suffered from an allergic reaction to the medication. A spokesperson with Palatin says the man who fell ill after taking the drug fully recovered and that the company “will work ... Read More